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Mycobacterium genavense is a recently defined fastidious organism that has been identified as a
cause of disseminated infection in patients with AIDS. We report the cases of two patients who
had advanced AIDS and a clinical syndrome of fever, anorexia, abdominal pain, diarrhea, and
weight loss. In addition, splenomegaly and lymphadenopathy were prominent in both cases, and
in one patient's case radiographic findings were suggestive of splenic abscesses. Mycobacteria
isolated from specimens of blood and bone marrow grew in liquid media but not on solid media.
The results of DNA probe tests for Mycobacterium tuberculosis and Mycobacterium avium com-
plex were false-positive for both patients. After treatment of the broth cultures to lyse red blood
cells, the results of DNA probe tests were negative for these pathogens. Amplification and se-
quencing of 16S rRNA with use of the polymerase chain reaction indicated that the mycobacte-
rial isolates from both patients had sequences identical to those previously reported for M.
genavense. One patient survived 5 months after diagnosis, the other 2 months after diagnosis;
only one patient responded (transiently) to antimycobacterial chemotherapy.
Improvements in antimicrobial therapy have led to in-
creased life-spans among patients infected with the human
immunodeficiency virus (HIV). These severely immuno-
compromised individuals are at increased risk for mycobac-
terial infections through either reactivation or new acquisi-
tion of the microorganisms. Disseminated mycobacterial
disease in the late stages of AIDS is most commonly the
result of infection with Mycobacterium avium complex
(MAC). Despite multidrug therapy, most patients' clinical
conditions improve only minimally.
In 1990 Hirschel et al. [1] reported the case of a patient
with advanced AIDS who developed a syndrome character-
ized by fever, anorexia, diarrhea, and weight loss. Staining of
biopsies of duodenum and bone marrow and blood buffy
coat samples revealed acid-fast bacilli (AFB), which grew in
liquid BACTEC medium but not on a variety of solid media.
The results of DNA probe tests were negative for Mycobacte-
rium tuberculosis and MAC. Findings of electron microscopy
and cell-wall lipid analyses were consistent with a mycobacte-
rium. More recently, Bottger et al. identified additional pa-
tients, mostly from Switzerland, with a similar clinical syn-
drome [2]. Moreover, amplification and sequencing of the
16S ribosomal RNA with use of the polymerase chain reac-
tion (PCR) demonstrated a high degree of homology be-
tween isolates from these patients and isolates from patients
with other mycobacterial species, especially M. simiae, as
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well as unique features; these features led to the designation
of a new species. Mycobacterium genavense [2].
To date only two small series of cases in which M. gena-
vense infection occurred outside of Europe have been pub-
lished: one series was from the United States [3], the other
was from Australia [4]. We report the cases of two patients
with M. genavenseinfection who were seen at The University
oflowa Hospitals and Clinics. review the published literature
on this infection. and highlight the unusual features of this
disease. We also reiterate an important potential problem
with the use of DNA probes for detection of M. tuberculosis
and MAC in specimens containing red blood cells.
Case Reports
Case 1. A 35-year-old homosexual man was found to be
seropositive for HIV in 1988. His CD4 lymphocyte count
was 150/J,LL and he received therapy with zidovudine. Apart
from a mild bout of Pneumocvstis carinii pneumonia and
recurrent perirectal ulcers (caused by herpes simplex), his
condition was stable until March 1992, when he developed
constant abdominal pain, diarrhea, and weight loss. At that
point his CD41ymphocyte count was 82/J,LL. Examination of
stool specimens revealed only Giardia cysts, but he failed to
respond to two courses of therapy with metronidazole. An
abdominal ultrasonogram showed splenomegaly. The pa-
tient became anemic, and biopsy of bone marrow revealed
AFB and multiple granulomata. The patient was treated with
rifampin, ethambutol, clofazimine, ciprofloxacin, and isonia-
zid, but his symptoms persisted. Endoscopy revealed candi-
dal esophagitis, and biopsy of the duodenum revealed AFB.
A computerized tomography (CT) scan showed hepato-
splenomegaly and mesenteric adenopathy. In October 1992
he had changes in his mental status and developed ataxia: a
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CT scan revealed multiple intracerebral lesions that were
suggestive of toxoplasmosis. He failed to respond to therapy
with pyrimethamine and clindamycin and died 2 weeks later.
Case 2. A 20-year-old heterosexual man was found to be
seropositive for HIV in April 1992. One month later he devel-
oped abdominal pain, diarrhea, and headache; a 30-lb
weight loss was also noted at this time. His CD41ymphocyte
count was 5/J.LL. An abdominal ultrasonogram revealed mild
splenic enlargement. Clostridium difficile toxin was detected
in specimens of his stool; he received a 2-week course of
metronidazole therapy because of diarrhea, which subse-
quently abated. In June 1992 he developed severe left-up-
per-quadrant pain, fever, and night sweats, although his CD4
lymphocyte count had risen to 85/J.LL while he was receiving
zidovudine therapy. A CT scan revealed splenic hypodensi-
ties and paraaortic lymphadenopathy. A biopsy of bone
marrow showed multiple granulomata and occasional AFB.
The patient started receiving therapy with ethambutol, ri-
fampin, ciprofloxacin, and clofazimine. As he experienced
adverse effects while receiving therapy with rifampin, ther-
apy with clarithromycin was substituted. His symptoms de-
creased over the next 2 months, and he began to gain weight.
A repeated CT scan revealed homogeneity of both the liver
and spleen. In August 1992 he developed a hemorrhagic left
pleural effusion. AFB were not seen in the pleural fluid, but
white pleural plaques were observed at thoracoscopy and a
biopsy revealed noncaseating granulomata. The patient de-
veloped respiratory failure postoperatively and died.
Microbiology
Samples of blood and bone marrow from each patient
yielded mycobacteria in BACTEC 13A (blood) or 12B(bone
marrow) bottles (Becton Dickinson Diagnostic Instrument
Systems, Sparks, MD) in 4-6 weeks. DNA probe analyses
(Gen-Probe, San Diego, CA) of both samples from both pa-
tients were initially positive for M. tuberculosis as well as for
MAC. We subsequently ascertained that blood and bone
marrow were interfering with the luminescent probe tests (a
finding recently reported by Evans et al. [5]), which resulted
in false-positive readings. To eliminate this problem, as rec-
ommended by those authors, we treated a 1.8-mL aliquot
from each positive BACTEC bottle with 0.2 mL of a 1%
SDS/5 mM EDTA solution, pH 8.0, and vigorously vortexed
it before centrifugation at 15,000g for 10 min. The proce-
dure was repeated one time, and ultimately the pellet was
washed with 2 mL of water before the probe assay was per-
formed. DNA probe analysis of samples treated in this man-
ner was negative. We have performed this procedure on sam-
ples that are known to be positive, and it does not interfere
with true-positive results ofDNA probe analysis. In our labo-
ratory all BACTEC specimens that yield mycobacteria are
routinely treated in the above-described manner if they con-
tain blood or bone marrow before the luminescent probe
procedure is performed.
5' CGG ATA GGA CCA CGG GAT GCA TGT CT* TGT GGT GGA AAG M. tuberculosis
T-- A-C T-* M. genavense
T-- A-C T-* Bone Marrow
PatleMl
T-- A-C T·* Blood
PatleM2
T-- A-C T-* Bone Marrow
PatleM2
Figure 1. 16S rRNA sequences of M. tuberculosis and M. gena-
vense from clinical samples. The first nucleotide corresponds to
position 176 of Escherichia coli 16S rRNA. Asterisks represent de-
letions relative to E. coli. M. tuberculosis rRNA is shown as a refer-
ence, and only nucleotides of M. genavense that are different from
those of M. tuberculosis are shown.
Although the mycobacteria initially cultured in BACTEC
bottles were successfully subcultured in other bottles, no
growth was obtained on any solid media despite the use of
triplicate sets (incubated at 30°C, 35°C, and 42°C) of Mid-
dlebrook 7H 10 agar, Lowenstein-Jensen agar, and blood
agar as well as enriched chocolate agar for the isolation of
Mycobacterium haemophilum [6]. Analysis of 16S ribosomal
RNA was carried out by PCR amplification and sequencing
with use of the primers and conditions previously described
[2]. The mycobacterial isolates from both patients had se-
quences identical to those reported for M. genavense [2] (fig-
ure I).
Discussion
As clinical experience with severely immunocompromised
AIDS patients has accumulated, more infections due to fas-
tidious environmental mycobacterial species have become
apparent. Examples of these organisms include M. avium. M.
intracellulare, M. kansasii. M. simiae, M. haemophilum. and
M. malmoense; clearly M. genavense should be included in
this list [I -4, 6-12].
In previously reported cases of M. genavense infection in
AIDS patients, gastrointestinal disease was emphasized; our
two cases illustrate the prominence ofsplenic involvement in
these patients. Patient I had significant splenomegaly, and
for patient 2 the findings on CT scan were highly suggestive
ofsplenic abscesses, which appeared to respond to antimyco-
bacterial therapy. Khalil et al. [13] included M. tuberculosis
and MAC in the differential diagnosis of splenic abscesses in
HIV-positive patients. In the recent series of cases reported
by Wald et al. [3], four of seven patients with M. genavense
infection had splenic involvement; two patients had spleno-
megaly, one patient's spleen ruptured during splenectomy,
and examination ofautopsy-obtained specimens of the third
patient's spleen revealed AFB. Four of 18 patients with dis-
seminated M. genavense infection whose cases were reported
by Bottger et al. [2] had splenomegaly, as did two of three
children whose cases were recently reported by Nadal et al.
[14]. Thus, we believe that splenic enlargement and splenic
abscesses are commonly associated with M. genavense infec-
tion.
GD 1994;18 (March) Mycobacterium genuveflse and AIDS 457
Clinicians should be alerted to the possibility of M. gena-
vense infection in AIDS patients who present with a syn-
drome of fever, anorexia, weight loss, abdominal pain, diar-
rhea, splenomegaly, and anemia. Laboratory evidence for
diagnosis of this infection consists of detection of AFB in
blood, bone marrow, or gut tissue specimens as well as the
growth of mycobacteria in liquid media and the failure of
growth on subculture on solid agar. Liquid cultures (BAC-
TEC 12B or 13A) should be maintained for at least 6-12
weeks [15, 16]. Some laboratories have detected limited
growth of M. genavense on solid media comprised of either
Middlebrook 7H 11 agar supplemented with mycobactin J
[15] or Middlebrook 7H 10 agar containing charcoal and
yeast extract [16]. This growth may require months of incu-
bation. Recently, Bottger et al. [2] described 16S rRNA se-
quencing for the definitive identification of M. genavense.
This approach should be considered when fastidious myco-
bacteria that fail to grow on solid media are encountered.
The difficulties with cultivation of M. genal'ense have pre-
cluded characterization of antimicrobial drug susceptibili-
ties, and treatment of M. genavense infection has thus been
based on knowledge of M. aviutn susceptibilities. Variable
results have been observed with multiple chemotherapeutic
regimens [2, 3, 14]. Survival after initiation of therapy for M.
genavense infection has ranged from 2 months to > 14
months [1,3]. One ofour patients had little or no response to
therapy and died after 5 months (death was caused by an-
other opportunistic infection). The second patient's symp-
toms decreased while combination therapy was adminis-
tered, but this patient died after 2 months. A granulomatous
pleural process was noted shortly before death. It is difficult
to assess whether infection with M. genavense contributes
substantially to shortened life-spans since most patients who
are infected with M. genavense have multiple opportunistic
infections.
Little is known about the pathogenesis and epidemiology
of M. genavense infection. Hirschel et al. [1] documented
bacteria within the cytoplasm of histiocytes in pathology
specimens and demonstrated growth of bacteria in vitro
within mouse peritoneal macrophages. Because of the promi-
nence of gastrointestinal disease, it has been suggested that
infection is acquired via an oral route [1]. Although most
cases ofM. genavenseinfection in patients with AIDS identi-
fied to date have occurred in central Europe, the geographic
range of the organism is unknown. Our cases together with
those recently reported from Seattle [3] bring the total num-
ber of documented M. genavense infections in the United
States to nine. Nothing is known about the ecology of this
mycobacterium, although a recent report indicated that in-
fection due to M. genavense occurs in pet birds [17]. Future
studies of M. genavenseinfection should be directed at defin-
ing the epidemiology and mode of acquisition of this patho-
gen as well as at determining rapid methods of diagnosis and
techniques for assessing antimicrobial drug susceptibilities.
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